Imperial Innovations Group Regulatory News (IVO)

RNS REACH

28 June 2016

Imperial Innovations Group plc

Storm Therapeutics raises £12m to develop novel cancer therapeutics

Imperial Innovations Group plc (AIM: IVO, 'the Group', 'Innovations') announces that portfolio company Storm Therapeutics (or the 'Company') has completed a £12.0 million Series A fundraising which will be used for the identification of small molecules that target RNA-modifying enzymes as the basis for the development of new cancer therapies.

Innovations led the seed funding round for Storm Therapeutics (formerly Iceni Therapeutics) in May 2015 and has now committed a further £3.0 million to the Series A funding round, alongside existing investor Cambridge Innovation Capital and new investors Merck Ventures BV and Pfizer Venture Investments. As a result of this new investment, Innovations will hold a 22.3% stake in the issued share capital of the Company.

Storm Therapeutics is a drug discovery and development business focused on the identification and development of small molecules that target RNA-modifying enzymes. The company is a spin-out from the University of Cambridge's Gurdon Institute and was created to commercialise the ground-breaking work of its founders, Professor Tony Kouzarides and Professor Eric Miska, in the field of RNA epigenetics.

RNA (ribonucleic acid) is the template of all protein synthesis and has key regulatory functions in the cell. There is growing understanding of the importance of RNA modification in the development of cancer, opening up novel therapeutic targets in cancer treatment.

Professors Kouzarides and Miska and their research groups have identified certain RNA-modifying enzymes against which Storm Therapeutics intends to develop therapeutics, using intellectual property licensed from Cambridge Enterprise (the commercialisation arm of the University of Cambridge). The proceeds of the funding will be used to identify small molecule modulators of these novel targets in RNA modification pathways and develop them into new classes of anti-cancer treatments.

Rob Woodman, Director of Healthcare Ventures at Imperial Innovations, said:

"We are delighted to be working with the founders and co-investors to make Storm Therapeutics a leader in therapeutic modulation of RNA modifying enzymes.

"Storm Therapeutics is a classic example of our model - helping world-leading scientists to turn their outstanding research into exciting early-stage companies by providing long-term funding and building great syndicates of like-minded co-investors."

For further information contact:

Notes to editors

About Imperial Innovations - www.imperialinnovations.co.uk 

Imperial Innovations Group plc ("Innovations") creates, builds and invests in pioneering technology companies and licensing opportunities developed from outstanding scientific research from the 'Golden Triangle', the geographical region broadly bounded by London, Cambridge and Oxford. This area has an unrivalled cluster of outstanding academic research and technology businesses, and is home to four of the world's top 10 universities, as well as leading research institutions, the cream of the UK's science and technology businesses and many of its leading investors.

Innovations supports scientists and entrepreneurs in the commercialisation of their ideas, through the licensing of intellectual property, by leading the formation of new companies, by recruiting high-calibre management teams and by providing investment and encouraging co-investment. Innovations remains an active investor over the life of its portfolio companies, with the majority of Innovations' investment going into businesses in which it is already a shareholder.

Since becoming a public company in 2006, Innovations has raised more than £440 million of equity from investors, which has enabled it to invest in some of the most exciting spin-outs to come out of UK academic research. In addition, the Group has agreed £80.0 million in loan facilities from the European Investment Bank (EIB).

Between Innovations' admission to AIM (August 2006) and 31 July 2015, Innovations had invested a total of £236.8 million across its portfolio companies, which had raised collectively investment of £1.3 billion.